Our observations suggest that SARS-CoV-2-specific CD4+ and CD8+ T-cell responses should be considered to better evaluate vaccination and public health strategies, and assessed together with neutralizing antibody titers to predict protection from infection and severe COVID-19. The gene discussed is CD4; the disease is COVID-19.